Clinical efficacy and safety of first-line nilotinib or imatinib therapy in patients with chronic myeloid leukemia-Nationwide real life data.

Autor: Belohlavkova P; 4th Department of Internal Medicine and Haematology, University Hospital Hradec Kralove and Charles University, Prague, Czech Republic., Zackova D; Department of Internal Medicine-Haematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic., Klamova H; Institute of Haematology and Blood Transfusion, Prague, Czech Republic., Faber E; Department of Haemato-oncology, University Hospital Olomouc and Palacky University, Olomouc, Czech Republic., Karas M; Department of Haemato-oncology, University Hospital Plzen and Charles University, Plzen, Czech Republic., Stejskal L; Department of Haemato-oncology, University Hospital Ostrava and Ostrava University, Ostrava, Czech Republic., Cmunt E; 1st Department of Internal Medicine-Haematology, General University Hospital and Charles University, Prague, Czech Republic., Cerna O; Department of Internal Medicine-Haematology, University Hospital Kralovske Vinohrady and Charles University, Prague, Czech Republic., Jeziskova I; Department of Internal Medicine-Haematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic., Machova Polakova K; Institute of Haematology and Blood Transfusion, Prague, Czech Republic., Zak P; 4th Department of Internal Medicine and Haematology, University Hospital Hradec Kralove and Charles University, Prague, Czech Republic., Jurkova T; Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic., Chrapava M; Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic., Mayer J; Department of Internal Medicine-Haematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic.; Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.
Jazyk: angličtina
Zdroj: Cancer medicine [Cancer Med] 2024 Sep; Vol. 13 (17), pp. e70158.
DOI: 10.1002/cam4.70158
Abstrakt: Background: To evaluate the outcomes of first-line imatinib versus nilotinib treatment for chronic myeloid leukemia in the chronic phase (CML-CP) in real-world clinical practice.
Methods: A propensity score analysis was performed to eliminate imbalances between the treatment groups. In the analysis, 163 patients in the nilotinib group and 163 patients in the matched imatinib group were retrospectively evaluated.
Results: Nilotinib-treated patients achieved complete cytogenetic response (CCyR) and major molecular response more rapidly than imatinib-treated patients. However, there was no significant difference in 5-year overall survival (OS) or progression-free survival (PFS) between the two groups (OS: 94.3% vs. 90.5%, p = 0.602; PFS: 92.9% vs. 88.0%, p = 0.614). Nilotinib-treated patients had a higher failure-free survival (FFS) and event-free survival (EFS) than imatinib-treated patients (FFS: 71.7% vs. 54.3%, p = 0.040; EFS: 71.7% vs. 53.5%, p = 0.025).
Conclusions: This retrospective analysis from clinical practice did not confirm any benefit of frontline nilotinib treatment for OS and PFS; however, it did demonstrate higher FFS and EFS in the nilotinib cohort.
(© 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje